Showing Results for
- Academic Journals (34)
Search Results
- 34
Academic Journals
- 34
-
From:PharmacoEconomics and Outcomes News (Vol. 578)A cost-effectiveness analysis favours the use of bivalirudin or fondaparinux-based therapy over unfractionated heparin (UFH)- or enoxaparin sodium-based therapy, for anticoagulation in treating patients with non-ST...
-
From:Expert Review of Cardiovascular Therapy (Vol. 2, Issue 5) Peer-ReviewedResults from the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to reduced Clinical Events (REPLACE)-2 trial have confirmed that bivalirudin (Angiomax[R], The Medicines Company) is a...
-
From:Future Cardiology (Vol. 4, Issue 4) Peer-ReviewedA major new study led by Gregg W Stone, professor of medicine at Columbia University Medical Center, NY, USA, has demonstrated that direct treatment with the thrombin inhibitor bivalirudin offers a significantly...
-
From:Formulary (Vol. 42, Issue 3) Peer-ReviewedIn a large, multi-center, randomized, open-label, prospective trial named the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial, monotherapy with the anti-thrombotic agent bivalirudin, when...
-
From:Expert Review of Cardiovascular Therapy (Vol. 2, Issue 2) Peer-ReviewedCoronary artery thrombosis is usually triggered by platelet-rich thrombus superimposed on a spontaneously or mechanically disrupted atherosclerotic plaque. Thrombin and platelets both play a role in this process....
-
From:PharmacoEconomics and Outcomes News (Vol. 615)Bivalirudin use is associated with lower costs than heparin in unselected patients who undergo percutaneous coronary intervention (PCI), say researchers who presented their findings at the Annual Scientific Symposium on...
-
From:PLoS ONE (Vol. 16, Issue 10) Peer-ReviewedBackground The safety and efficacy profile of bivalirudin has not been examined in a randomised controlled trial of patients undergoing rescue PCI. Objectives We conducted an open-label, multi-centre, randomised...
-
From:Expert Review of Cardiovascular Therapy (Vol. 8, Issue 12) Peer-ReviewedAuthor(s): David A Van De Car [[dagger]â ] 1 , Sunil V Rao 2 , E Magnus Ohman 2 Keywords : acute coronary syndrome; anti-thrombotic; bivalirudin; direct thrombin inhibitor(s) Thrombin inhibition plays an...
-
From:Future Cardiology (Vol. 4, Issue 4) Peer-ReviewedAuthor(s): Rik Hermanides 1 , Jan Paul Ottervanger [[dagger]] 2 Keywords: acute coronary syndromes; bivalirudin; fibrinolysis; glycoprotein IIb/IIIa inhibitors; percutaneous coronary intervention; ST-elevation...
-
From:Journal of Hematology & Oncology (Vol. 13, Issue 1) Peer-ReviewedAs our understanding on coronavirus disease 2019 (COVID-19) deepens, it is increasingly recognized that COVID-19 is more than a respiratory condition. Thrombocytopenia and thromboembolic complications are a composite...
-
From:Reactions Weekly (Issue 1251)[S] A 52-year-old man developed heparin-induced thrombocytopenia (HIT) after receiving low molecular weight heparins and unfractionated heparin [therapeutic indications not clearly stated]; he was successfully...
-
From:Indian Journal of Anaesthesia (Vol. 56, Issue 1) Peer-ReviewedByline: Dharmesh. Agrawal, Mohammed. Sayeed, Indira Rajani. Roy, K. Somaraja Sir, Heparin-induced thrombocytopenia (HIT) is defined as a decrease in the platelet count during or shortly following exposure to...
-
From:PLoS ONE (Vol. 10, Issue 5) Peer-ReviewedPercutaneous coronary intervention with bivalirudin plus bail-out glycoprotein IIb/IIIa inhibitors has been shown to be as effective as unfractionated heparin plus routine glycoprotein IIb/IIIa inhibitors in preventing...
-
From:Reactions Weekly (Issue 1342)Clinical study Bivalirudin monotherapy, compared with an anticoagulation regimen that includes a glycoprotein (GP) IIb/IIIa inhibitor, is associated with a significantly reduced risk of platelet reduction among...
-
From:Anaesthesia and Intensive Care (Vol. 41, Issue 2) Peer-ReviewedSUMMARY The purpose of this study was to assess whether simulation training can improve the clinician's ability to predict the effect of bivalirudin infusion. Six clinicians with experience using bivalirudin and...
-
From:Future Cardiology (Vol. 10, Issue 6) Peer-ReviewedAuthor(s): Nephertiti Efeovbokhan aff1 , Rami N Khouzam [*] aff1 , Ahmad Al-Fakhouri aff2 , Laura Salama aff3 KEYWORDS bivalirudin; carotid artery stenting; glycoprotein IIb/IIIa inhibitors; heparin; percutaneous...
-
From:Cardiology Research and Practice (Vol. 2018) Peer-ReviewedAim. This study sought to compare short- and long-term outcomes of drug-eluting stents (DESs) versus bare-metal stents (BMSs) implantation in patients with end-stage renal disease on hemodialysis (ESRD-HD) undergoing...
-
From:Expert Review of Cardiovascular Therapy (Vol. 2, Issue 3) Peer-ReviewedScientists from the University of New York, USA have reported that intra-arterial administration of bivalirudin (Angiomax[R], Medicines company) during endovascular treatment of stroke can facilitate reperfusion with...
-
From:Indian Journal of Pain (Vol. 33, Issue 2) Peer-ReviewedByline: Uma. Lakkaraju, Ram. Gurram Acute limb ischemia (ALI) is defined as any sudden decrease in limb perfusion causing a potential threat to limb viability. We are presenting a case of vasopressor-induced ALI...